RXRX
Recursion Pharmaceuticals Inc
3.70$
-8.6%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +5.2% | +27.0% | +6.8% | +81.1% | -82.7% | +226.9% | +29.6% | -72.9% | +586.7% | -81.8% | +18.5% | – | |
| – | -9.2% | +13.0% | -17.6% | +31.3% | +5.9% | +70.6% | -7.6% | +46.8% | -9.2% | -53.5% | -8.0% | – | |
| – | – | +212.9% | +123.9% | +169.0% | -159.2% | – | – | – | – | -169.5% | – | – | |
| – | -0.7% | -2.8% | +9.4% | +0.9% | +31.8% | +31.8% | -0.8% | -5.9% | -31.2% | +5.5% | +2.0% | – | |
| – | +4.3% | +3.1% | +1.4% | +18.6% | +104.4% | -29.2% | -14.6% | -10.8% | -19.1% | +2.8% | +20.1% | – | |
| – | +0.9% | -1.0% | +7.2% | +6.2% | +56.2% | +5.0% | -4.9% | -15.6% | -20.8% | +4.7% | +7.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +4.0% | -23.1% | +1,870.0% | +40.4% | +9.4% | -16.0% | -5.5% | +73.5% | -98.7% | +3,081.8% | -11.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -352.9% | – | – | – | -95.8% | -2,357.1% | – | – | +566.7% | -23,120.0% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.